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Abstract
Background: Middle age obesity is recognized as a risk factor for Alzheimer’s disease (AD) although a mechanistic linkage
remains unclear. Based upon the fact that obese adipose tissue and AD brains are both areas of proinflammatory change, a
possible common event is chronic inflammation. Since an autosomal dominant form of AD is associated with mutations in
the gene coding for the ubiquitously expressed transmembrane protein, amyloid precursor protein (APP) and recent
evidence demonstrates increased APP levels in adipose tissue during obesity it is feasible that APP serves some function in
both disease conditions.
Methodology/Principal Findings: To determine whether diet-induced obesity produced proinflammatory changes and
altered APP expression in brain versus adipose tissue, 6 week old C57BL6/J mice were maintained on a control or high fat diet
for 22 weeks. Protein levels and cell-specific APP expression along with markers of inflammation and immune cell activation
were compared between hippocampus, abdominal subcutaneous fat and visceral pericardial fat. APP stimulation-dependent
changes in macrophage and adipocyte culture phenotype were examined for comparison to the in vivo changes.
Conclusions/Significance: Adipose tissue and brain from high fat diet fed animals demonstrated increased TNF-a and
microglial and macrophage activation. Both brains and adipose tissue also had elevated APP levels localizing to neurons and
macrophage/adipocytes, respectively. APP agonist antibody stimulation of macrophage cultures increased specific cytokine
secretion with no obvious effects on adipocyte culture phenotype. These data support the hypothesis that high fat diet-
dependent obesity results in concomitant pro-inflammatory changes in brain and adipose tissue that is characterized, in
part, by increased levels of APP that may be contributing specifically to inflammatory changes that occur.
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Introduction
Obesity, particularly in mid-life, is an increased risk factor for
AD independent of other conditions [1,2,3,4,5,6,7]. Particular
saturated versus unsaturated fat ingestion at midlife also increases
the risk of developing AD [8,9]. In addition, metabolic syndrome
and diabetes, often comorbid with obesity, are factors of increased
risk for AD in some [6,7,10,11] but not all studies [12].
Interestingly, late life obesity and metabolic syndrome are either
not risk factors or actually decrease the risk of AD in several
studies [3,13,14]. Others have reported that obesity itself is
associated with poorer cognitive performance in humans
[15,16,17] as well as decreased brain volumes [18] independent
of age or disease. In spite of this abundance of correlational data, a
particular mechanism linking the pathophysiology of obesity to the
brain changes of AD remains unclear.
One possibility of linking the conditions focuses on the biology
of amyloid precursor protein, APP. It is expressed in the brain
primarily by neurons [19] where it can be metabolized to Ab1-40
and 1-42 peptides which aggregate to form amyloid plaques
characteristic of AD [20]. Moreover, mutations in the gene coding
for APP [21] or its protease presenilins [22,23,24] are responsible
for a rare autosomal dominant form of disease. Therefore, APP
and its proteolytic fragments are likely to play a central role in the
pathophysiology of AD.
Recent data suggests that APP expression or function may alsobe
involved in the pathophysiology of obesity. It is known that adipose
tissue [25,26,27] and adipocyte cell lines [27] express APP. More
importantly, adipose APP and Ab1-40 plasma levels increase in
obese individuals [25,26] and plasma Ab1-42 and 1-40 levels
correlate with increased body fat in humans [28,29]. Rodent studies
have examined the brain in a variety of diet-induced obesity
paradigms confirming that brain changes leading to increased Ab
levels occur in both AD transgenic [30,31] and wild type mice [32].
These findings indicate that changes in APP expression or function
may be coordinated across diverse tissue types.
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with C57BL6/J mice to determine whether changes in APP
expression occurred similarly in brain versus visceral and
subcutaneous fat depots in correlation with simultaneous proin-
flammatory changes in each tissue.
Results
High fat diet feeding increased brain levels of APP and
multiple pro-inflammatory proteins compared to control
diet fed mice
In order to establish the system for comparing changes in
adipose tissue to brain, a standard high fat diet feeding paradigm
was used. 24 six week old weight matched male C57BL6/J mice
were placed on either a 21.2% by weight high fat diet or a 5.5% by
weight control diet, ad libitum, beginning at six weeks of age
(Table 1). Twelve animals in each group were weighed weekly for
22 weeks and mean (+/2SD) weight gain per group was graphed
versus time (Fig. 1). By week five the high fat diet fed mice
demonstrated a statistically significant increase in weight gain over
the control diet fed mice (Fig. 1). After 22 weeks, the high fat diet
fed mice had on average a 217% total weight gain, whereas
control diet fed mice had on average only a 158% total weight
gain. To examine whether proinflammatory or degenerative
changes were occurring in the brains of high fat diet fed animals,
Western blot analysis of hippocampi from both groups was
performed. As expected, high fat diet fed mice demonstrated a
significant increase in expression of APP when compared to
control diet fed mice (Figs. 2, 3). This did not correlate with any
change in protein levels of the postsynaptic protein marker,
PSD95, or the presynaptic marker, synaptophysin (Figs. 2, 3).
However, there was a significant increase in astrocyte GFAP
protein levels, but no change in microglia CD68 protein levels
associated with the high fat diet fed mice. Interestingly, two
markers of inflammatory change, iNOS and Cox-2 were not
altered in hippocampi of high fat diet versus control diet fed
animals (Figs. 2, 3). Although Cox-2 protein levels were not
altered, we further examined enzyme activity and total brain
prostaglandin (PG) levels (a sum of PGE2, PGD2, 6-ketoPGF1a,
PGF2a, and thromboxane B2) were quantitated from animals in
each diet group. Interestingly, high fat diet fed animals
demonstrated a significant increase in brain prostaglandin levels
compared to control fed animals indicating elevated arachidonic
acid metabolism in spite of no significant change in protein levels
of Cox-2 (Fig. 3). Additionally, high fat diet feeding did not
significantly alter phosphorylation levels of tau protein [33] as
assessed using the PHF-1 antibody (Figs. 2, 3). These data
demonstrate that high fat diet feeding stimulates an increase in
APP protein levels in the brain which correlates with an increased
level of gliosis and elevated prostaglandin levels. This supports the
notion that the chronic inflammatory changes associated with
peripheral tissue during diet-induced obesity extend into the brain.
Moreover, these changes are consistent to some degree with those
that are observed during Alzheimer’s disease.
Proinflammatory protein immunoreactivity increased in
neurons in brains from high fat diet versus control fed
mice
Although the Western analysis demonstrated significant protein
changes in high fat diet fed mice compared to controls, the cellular
identity of those proteins was unknown. Understanding the
cellular contribution was of particular interest since APP is
expressed by several cells in the brain. In order to determine which
cells may be responsible for the changes in protein levels,
immunohistochemistry was performed from the collected hippo-
campi. In agreement with the fact that the majority of APP is
expressed by neurons in the brain [34] both high fat and control
diet fed mice displayed neuronal immunoreactivity for APP with a
diet-induced increase in immunoreactivity in the high fat diet fed
mice (Fig. 4). To examine whether APP was increasingly processed
or deposited as the proteolytic fragment, beta amyloid (Ab), brain
sections were also immunostained using an anti-mouse Ab
antibody. However, there was no obvious change in intensity or
distribution of Ab immunoreactivity in the different diet fed
animals (Fig. 4). Cox-2, iNOS, and CD68 histologic analysis
demonstrated what appeared to be elevated immunoreactivity for
each (Fig. 4) although this did not reach the level of statistical
significance via Western blot analysis (Fig. 3). Interestingly, the
immunoreactivity for both Cox-2 and iNOS in high fat diet fed
animals appeared within neurons as opposed to glia (Fig. 4).
Although, the difference in immunoreactivity for reactive
microglia (CD68) was modest, there was a clear increase in
astrocyte GFAP immunoreactivity in the high fat diet fed animals
compared to controls demonstrating that at least an astrogliosis
was occurring (Fig. 4). These data demonstrated that high fat diet
Figure 1. Average weight gain per week for mice fed a high fat
versus control diet. C57BL6/J mice at 6 weeks of age and weight
matched were fed, ad libitum, a control (5.5% fat/weight) or high fat
(21.2% fat/weight) diet for 22 weeks. 12 animals in each group were
weighed weekly and mean (+/2SD) weight gain per group was
graphed versus time. *p=0.001.
doi:10.1371/journal.pone.0030378.g001
Table 1. Commercial diet formulations for control and high
fat diet.
Control Diet High Fat Diet
protein (% by weight) 22.0 17.3
carbohydrate (% by weight) 40.6 48.5
fat (% by weight) 5.5 21.2
energy density (Kcal/g) 3.0 4.5
doi:10.1371/journal.pone.0030378.t001
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Western blot analysis detected increased protein levels of APP
within neurons, the proinflammatory changes were not limited to
any particular cell type in the brain but instead appeared to
include a multi-cellular response.
In spite of the fact that microglia and astrocytes demonstrated
immunoreactivity for typical activation markers, CD68 and GFAP
respectively, this was not necessarily a reflection of a contribution
to any proinflammatory changes that were occurring. As a means
of assessing this, microglia were further examined based upon our
prior experience with isolating these cells from adult animals [35].
For comparison, microglial secreted TNF-a levels were compared
to values derived from resting peritoneal macrophage as a positive
control. In general microglia isolated from the 22 week old control
fed animals secreted far less TNF-a when compared to their
peripheral cell counterparts (Fig. 5). However, microglia from high
fat diet fed mice secreted significantly more TNF-a than the
control diet fed animals (Fig. 5). This was entirely consistent with
the subtle increase in CD68 immunoreactivity observed even
though quantified Western blot analysis revealed no significant
difference in CD68 protein levels in the brains of high fat diet fed
mice compared to controls. Taken together, these data support the
idea that proinflammatory changes occur in brains of high fat diet
fed animals. These involved not only neuronal upregulation of
proteins but also increased cytokine secretion from reactive glia.
High fat diet feeding increased APP and TNF-a protein
levels compared to control diet fed mice in both
subcutaneous and visceral fat depots
Based upon the changes observed in the brain, adipose tissue
was next examined to determine whether similar changes in
proinflammatory protein expression occurred in the periphery.
Because visceral and subcutaneous fat depots can have altered
protein expression changes during diet-induced obesity
[36,37,38,39] both types of adipose reservoirs were assessed. To
begin comparing protein changes between brain and adipose
tissue, Western blot analysis was again performed. Subcutaneous
abdominal fat and visceral pericardial fat were examined as
representative samples of two distinct fat depots. Precisely as
observed in the brain, high fat diet fed mice demonstrated a
significant increase in APP protein levels in both fat depots over
control diet fed mice (Figs. 6, 7). To again assess if there was a
proinflammatory change, the two proinflammatory protein
markers quantified from brain, iNOS and Cox-2, were next
examined in the fat depots. Consistently, the diets demonstrated
no difference in either iNOS or Cox-2 protein levels in either type
of adipose tissue (Figs. 6, 7). However, based upon the fact that
microglial-secreted TNF-a levels were increased in high fat diet
fed mice and TNF-a elevations are a well characterized change in
adipose tissue from obese individuals [40,41] or animals [42], we
next quantified TNF-a protein levels. Similar to the changes
observed from brain microglia, both visceral and subcutaneous fat
depots demonstrated increased TNF-a levels compared to pair fed
controls (Figs. 6, 7). These data demonstrate that although there
were no significant differences between visceral and subcutaneous
fat depots, the overall proinflammatory changes were consistent
between adipose tissue and brain during high fat diet feeding. In
particular, the proinflammatory proteins, Cox-2 and iNOS, were
not significantly increased in either the brain or adipose tissue in
spite of the observed elevation in TNF-a from both tissue types.
Perhaps the most interesting observation was that APP levels
increased in both brain and adipose tissue. This demonstrated that
a coordinated, increased expression of APP occurred in the brain
and adipose tissue upon diet-induced obesity along with
acquisition of proinflammatory tissue phenotypes.
Adipose tissue APP immunoreactivity from high fat diet
fed animals localized to adipocytes and macrophage
Although brain changes in APP were determined to be
neuronally localized it was not likely that the increased APP levels
in adipose tissue were also neuronal. Therefore, to identify the
cellular origin of the increased APP levels in high fat diet fed
adipose tissue immunohistochemistry was again performed. In
both subcutaneous (Fig. 8) and visceral (Fig. 9) adipose tissue
increased APP immunoreactivity was observed in high fat diet fed
Figure 2. APP and GFAP protein levels were increased in
hippocampi of high fat versus control diet fed mice. C57BL6/J
mice at 6 weeks of age and weight matched were fed, ad libitum,a
control (5.5% fat/weight) or high fat (21.2% fat/weight) diet for 22
weeks. Hippocampus samples were collected from 5 animals for each
diet. Comparable age hippocampi from APP
-/- mice were collected as
negative controls for antibody specificity. The tissue was lysed, resolved
by 10–15% SDS-PAGE and Western blotted using anti-synaptophysin,
PSD95, APP, iNOS, Cox-2, GFAP, phospho-tau (PHF-1), CD68, bIII tubulin
(neuronal loading control), a-tubulin and actin (general loading control)
antibodies. Arrowheads indicate bands of interest when nonspecific
bands are present. Antibody binding was visualized by chemilumines-
cence. Blots from all animals in each diet are shown.
doi:10.1371/journal.pone.0030378.g002
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PLoS ONE | www.plosone.org 3 January 2012 | Volume 7 | Issue 1 | e30378Figure 3. APP and GFAP protein and total prostaglandin levels were increased in the hippocampi of high fat versus control diet fed
mice. Optical densities of the Western blotted hippocampal proteins (APP, CD68, iNOS, Cox-2, GFAP, synaptophysin, PSD95, and phospho-tau) from
the control and high fat diet Western blots were normalized against their respective averaged O.D. values of combined a-tubulin + bIII tubulin + actin
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during brain analysis, immunostaining of the two different adipose
depots with anti-mouse Ab antibody did not demonstrate a robust
increase in immunoreactivity in high fat diet fed animals nor any
plaque-type patterns (Figs. 8, 9). Although prior work has
demonstrated increased adipocyte APP immunoreactivity in
samples from obese humans, it was possible that the increased
APP immunoreactivity observed in our animal paradigm was also
localized to macrophage. Our prior work has shown that
monocytic lineage cells express APP and levels increase upon
differentiation and activation [43,44,45]. Moreover, a variety of
studies have demonstrated that increased macrophage infiltration
into adipose tissue occurs during diet-induced obesity [46,47,48].
Interestingly, both subcutaneous and visceral adipose tissue
demonstrated increased immunoreactivity for CD68 to identify
macrophage (Figs. 8, 9). Importantly, this increase in CD68
positive adipose tissue macrophage correlated precisely with the
slight increase in CD68 positive microglia observed in the brains of
high fat diet fed mice compared to controls (Fig. 4). Double
labeling immunohistochemistry was performed to determine
whether a portion of the increased APP immunoreactivity
observed was within adipose tissue infiltrated macrophage. In
either type of adipose tissue a population of the APP immuno-
reactive cells also co-localized with CD68 immunoreactivity
indicating that both adipocytes and macrophage may be
responsible for the upregulation of APP observed in adipose tissue
of high fat diet fed animals (Fig. 10). Indeed, visceral adipose tissue
demonstrated nearly complete co-localization of APP with CD68
immunoreactivity. These results confirm that increased APP levels
observed in adipose tissue from high fat diet fed animals is multi-
cellular with a significant portion likely from the increasing
numbers of tissue infiltrating macrophage. This correlates with the
increased levels of brain APP observed in high fat diet fed mice as
well as the increased gliosis that occurs.
The APP agonist antibody, 22C11, increased macrophage
cytokine production but had no effect on viability, lipid
storage/accumulation, or TNF-a secretion in adipocytes
To begin examining whether increased expression of APP had
any role in altering the phenotype of macrophage or adipocytes,
primary murine cultures were generated from non-elicited
peritoneal macrophage and subcutaneous adipocytes and then
stimulated using an agonist antibody for APP [44]. We first
stimulated peritoneal macrophage with 1 mg/mL IgG1 (isotype
control) or 22C11 (APP agonist antibody) and measured cytokine
secretion (Fig. 11). The APP agonist, 22C11, stimulated a
significant increase in secretion of granulocyte-macrophage colony
stimulating factor (GM-CSF) which reportedly increases the
production of macrophages [49]. This was consistent with the
increase in immunoreactivity for CD68 (macrophages) in both
adipose tissue depots during high fat diet-induced obesity.
Stimulation with 22C11 also significantly increased secreted levels
of IFNc, a macrophage-activating factor, that plays a critical role
in immunostimulatory and immunomodulatory effects [50,51]. In
contrast, 22C11 stimulation significantly increased secreted IL-13
levels which is reportedly responsible for down-regulation of
macrophage activity and thereby inhibits the production of pro-
inflammatory cytokines and chemokines [52]. Although these
findings do not demonstrate precisely what secretory changes
APP-overexpressing macrophage may be exhibiting in situ during
diet-induced obesity, they do provide clear evidence that APP
stimulated changes in macrophage phenotype are complex with
alterations in both proinflammatory and anti-inflammatory
secretion that will need to be further resolved in vivo in the diet-
induced obesity model.
To assess any effect of APP on adipocyte phenotype, we next
stimulated primary murine abdominal subcutaneous fat derived-
adipocytes with 1 mg/mL IgG1 or 22C11 antibodies. Unlike the
macrophage studies, agonist antibody stimulation of adipocytes
did not produce any obvious change in phenotype. There was no
significant toxicity of the 22C11 or IgG1 stimulated adipocytes as
assessed by LDH release (Fig. 12A). Since TNFa levels were
increased under diet-induced obesity conditions in both adipose
tissue depots, TNFa secretion was measured from APP stimulated
adipocytes (Fig. 12B). However, the APP agonist, 22C11, did not
stimulate a significant change in TNFa secretion. To assess a
differentiative phenotype, stimulated adipocytes were stained and
quantified using Oil Red O (Fig. 12C and 12D) to examine lipid
storage/accumulation. APP stimulation with 22C11 produced no
changes in Oil Red O staining. Although a minor subset of all the
possible changes in adipocyte phenotype was examined, the data
thus far indicates that viability, proinflammatory secretion, and
differentiation state are not affected by APP signaling. This
suggests that further investigation is needed to fully understand the
role of APP in adipocyte biology both basally and during instances
of increased APP expression such as that which occurs during diet-
induced obesity.
Discussion
We demonstrate that a high fat diet feeding paradigm in
C57BL6/J mice drives a concomitant increase in protein levels of
APP in brain and visceral and subcutaneous adipose tissue
correlating with proinflammatory changes in a cell specific fashion.
APP protein levels increased within primarily neurons in the brain
and macrophage and adipocytes in adipose tissue of high fat diet
fed mice. This correlated with reactive gliosis and elevated
microglial TNFa production. This elevated proinflammatory,
neurodegenerative phenotype of the high fat diet fed brain
correlated with a similar increase in APP and TNFa levels in high
fat diet fed adipose tissue. This supports the idea that a particular
function of APP may contribute to the metabolic changes that
occur in each tissue during diet-induced obesity. At the very least,
the APP changes observed may serve as one of the growing list of
bio-markers that identify obesity-related changes.
In particular, we provide a crucial data set of comparison
changes in brain versus adipose tissue that was lacking from earlier
studies which have focused on a particular organ. Prior work from
human subjects has demonstrated increased adipose tissue APP
and plasma Ab levels in obese subjects [25,26,27,28,53] although
comparable brain data was not reported. Similarly, brain but not
adipose data from Alzheimer’s disease transgenic rodent studies
using diet-induced obesity paradigms have indicated that obesity
correlates with increased levels of brain Ab [30,31,54] although
not necessarily an increase in full length APP as we observed. Our
findings are in greater agreement with those of Thirumanagala-
kudi and colleagues who found using wild type C57BL6/J mice
that a high fat/high cholesterol diet induced increased brain
changes in APP, Ab, and diverse proinflammatory proteins [32]
loading controls (+/2SD) from 5 animals for each diet. Total brain PG levels were quantitated as a sum of PGE2, PGD2, 6-ketoPGF1a, PGF2a, and
thromboxane B2 in each diet group. *p,0.05 and **p,0.01.
doi:10.1371/journal.pone.0030378.g003
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PLoS ONE | www.plosone.org 5 January 2012 | Volume 7 | Issue 1 | e30378Figure 4. Hippocampi of high fat diet fed mice demonstrated microglial (CD68), astrocytic (GFAP), and neuronal (Cox-2, APP and
iNOS) immunoreactivity versus control diet mice. C57BL6/J mice at 6 weeks of age and weight matched were fed, ad libitum, a control (5.5%
fat/weight) or high fat (21.2% fat/weight) diet for 22 weeks. Tissue samples were collected, fixed in 4% paraformaldehyde, serially sectioned, and
immunostained. Tissue sections were immunostained using anti-APP, Ab, GFAP, CD68, Cox-2, and iNOS antibodies and antibody binding was
visualized using Vector VIP as the chromagen. Arrows indicate the location of APP immunoreactivity shown as an enlarged inset in upper right corner
of each panel. Representative images from 12 animals per condition are shown.
doi:10.1371/journal.pone.0030378.g004
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brain APP or Ab levels [55]. To link these diverse data sets we
suggest, that based upon our findings, a high fat feeding paradigm
producing a diet-induced obesity in animals expressing APP under
the control of its endogenous promoter is sufficient to increase APP
expression in both adipose and brain tissue simultaneous with
similar proinflammatory changes that occur in each tissue.
It is not clear what the exact stimulus is to increase APP levels in
the cell types in our paradigm although we speculate that
proinflammatory stimuli are responsible. It is well established that
obesity correlates with a host of increased circulating proinflam-
matory molecules [56,57,58,59] released by both adipocytes and
adipose macrophage [58,60,61]. Prior work from the 3T3-L1
adipocyte cell line has demonstrated that stimulation with TNF-a
is sufficient to increase APP expression [27]. We [43,44,45] as well
as others [62,63,64,65,66,67,68,69,70,71,72,73] have demonstrat-
ed that APP expression and plasmalemmal localization in
monocytic lineage cells, including macrophage and microglia,
increases during proinflammatory or degenerative conditions.
Finally, neurons themselves have a well established ability to
increase APP expression during diverse degenerative and inflam-
matory stimulations [74,75,76,77,78,79,80].
It is important to point out that focus of this work was on the
particular cellular changes in full-length APP rather than
assessment of APP processing to Ab. However, we did assess
potential Ab generation and deposition in both brain and visceral
and subcutaneous adipose tissue via immunostaining. Although
the mouse Ab-specific antibody detected no robust changes in
either tissue from control or high-fat diet fed mice it is possible that
Ab production was increased in parallel with the increased APP
protein levels observed in high fat diet-fed mice but was simply not
detectable via immunostaining. We have not ruled out the
possibility that a longer feeding paradigm and more sensitive
detection method such as an Ab ELISA might demonstrate a
significant difference in APP processing to increased levels of Ab
between diets. Indeed, prior work has already demonstrated that
high fat/cholesterol feeding increases Ab levels in the murine
brain [32]. This indicates, perhaps not surprisingly, that although
Figure 5. Microglia but not peritoneal macrophage demon-
strated increased TNF-a secretion. C57BL6/J mice at 6 weeks of age
and weight matched were fed, ad libitum, a control (5.5% fat/weight) or
high fat (21.2% fat/weight) diet for 22 weeks. Microglia were isolated
from brains for comparison to non-elicited peritoneal macrophage.
Isolated microglia or macrophage from control and high fat diet fed
mice were plated overnight in serum free DMEM/F12 media and
secreted TNF-a levels were quantified by commercial ELISA. Data is the
average (+/2SD) of 12 animals/condition. *p,0.05.
doi:10.1371/journal.pone.0030378.g005
Figure 6. APP and TNF-a levels increased in visceral and
subcutaneous fat depots in high fat diet fed animals versus
controls. C57BL6/J mice at 6 weeks of age and weight matched were
fed, ad libitum, a control (5.5% fat/weight) or high fat (21.2% fat/weight)
diet for 22 weeks. Pericardial visceral (v) and abdominal subcutaneous
(s) fat were collected from 12 animals per group. The tissue was lysed,
resolved by 10-15% SDS-PAGE and Western blotted using anti-APP,
iNOS, Cox-2, TNF-a, and GAPDH (loading control) antibodies. Arrow-
heads indicate bands of interest when nonspecific bands are present.
Antibody binding was visualized by chemiluminescence. A representa-
tive blot of three animals per condition from a total of 12/condition
analyzed is shown.
doi:10.1371/journal.pone.0030378.g006
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processing and perhaps function(s) is unique based upon cell type
expression and requires future study. Regardless of what cell type
is potentially producing the Ab in brain and adipose tissue, the
peptide in either its oligomeric or fibrillar form has been shown in
numerous studies to be a potent stimulus for activating microglia
and monocyte/macrophage cells to acquire a reactive phenotype
[81,82,83,84,85,86,87,88]. Again, although processing of APP to
Ab was not the focus of this work, it is intriguing to consider that in
addition to proinflammatory stimuli potentially driving increased
APP expression, increased Ab production may act in a feed-
forward fashion to increase proinflammatory secretions in brain
and adipose tissue by directly stimulating microglia and macro-
phage, respectively. These data support the idea that limiting
inflammatory changes during diet induced weight gain may not
only attenuate pathologic events in peripheral organs but also
those in the brain. Indeed, it appears that use of non-steroidal anti-
inflammatory drugs during mid-life, in particular, may offer some
protective benefit against developing AD [89].
Although our study has focused specifically on changes related
to diet induced obesity it is difficult not to speculate that the
changes observed may be directly relevant to the mechanism of
Alzheimer’s disease. As already mentioned, mid-life obesity is a
well-recognized increased risk factor for developing AD
[1,2,3,4,6,7] and several rodent studies using transgenic mouse
models of AD have demonstrated that diet-induced obesity
paradigms increase Ab levels in the brain [30,31,54]. More
importantly, caloric restriction of these transgenic models is
Figure 7. APP and TNF-a protein levels increased in subcutaneous abdominal and visceral pericardial fat in high versus control diet
fed mice. Optical densities of the adipose protein Western blots from the control and high fat diet subcutaneous and visceral samples were
normalized against their respective GAPDH loading controls and averaged (+/2 SD) from 12 animals per each condition. *p,0.05, **p,0.01.
doi:10.1371/journal.pone.0030378.g007
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PLoS ONE | www.plosone.org 8 January 2012 | Volume 7 | Issue 1 | e30378Figure 8. APP, CD45, and CD68 immunoreactivity increased in the subcutaneous (abdominal) fat from high fat versus control diet
fed mice with no robust change in Ab immunoreactivity. C57BL6/J mice at 6 weeks of age and weight matched were fed, ad libitum, a control
(5.5% fat/weight) or high fat (21.2% fat/weight) diet for 22 weeks. Subcutaneous abdominal adipose tissue was collected, immersion fixed in 4%
paraformaldehyde, sectioned, and immunostained using anti-APP, Ab, CD45 and CD68 antibodies and antibody binding visualized using Vector VIP
as the chromogen. Representative images from 12 animals per condition are shown.
doi:10.1371/journal.pone.0030378.g008
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particularly interesting that microglia isolated from high fat diet
fed mice basally secreted elevated levels of TNFa compared to
microglia from control diet fed mice. The ability to isolate these
cells acutely from adult mouse brains without the confound of
prolonged in vitro culturing in serum containing conditions allows
us to quantify with confidence the basal microglial secretory
phenotype in the brain during either diet paradigm. The elevated
Figure 9. APP, CD45, and CD68 immunoreactivity increased in the visceral (pericardial) fat from high fat versus control diet fed
mice with no robust change in Ab immunoreactivity. C57BL6/J mice at 6 weeks of age and weight matched were fed, ad libitum, a control
(5.5% fat/weight) or high fat (21.2% fat/weight) diet for 22 weeks. Visceral pericardial adipose tissue was collected, immersion fixed, sectioned, and
immunostained using anti-APP, Ab, CD45 and CD68 antibodies and antibody binding visualized using Vector VIP as the chromogen. Representative
images from 12 animals per condition are shown.
doi:10.1371/journal.pone.0030378.g009
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elevated levels of total prostaglandins in the high-fat diet fed mice.
Although we did not attempt to determine effects of APP
stimulation on neuronal phenotype in this study it is interesting
to speculate that APP-dependent stimulation of neurons may lead
directly to increased neuronal prostaglandin production as well as
generation of Ab that may be direct stimuli for the increased
microglial TNFa secretion that occurred in high-fat diet fed
brains. This APP-dependent mechanism linking generation of
these proinflammatory mediators with gliosis would certainly be
reasonable to consider during similar degeneration events in AD.
Perhaps even more interesting is the possibility that APP
dependent proinflammatory events contribute to the classic
inflammatory changes commonly observed in peripheral adipose
tissue during diet-induced obesity. For instance, based upon the
increased APP levels observed in macrophage and adipocytes, we
examined a role for APP in regulating the phenotype of these cells.
Although we were unable to determine any phenotype change in
adipocyte downstream of APP stimulation, macrophage exhibited
a significant increase in secretion of three particular cytokines out
of the 40 analyzed that may be relevant to adipose changes
observed during high fat diet feeding. APP stimulation increased
macrophage secretion of GM-CSF, IFNc, and IL-13. GM-CSF
has a well characterized role in regulating infiltration of
macrophage into adipose tissue [91]. An APP-dependent increase
in GM-CSF secretion would certainly help to explain some of the
observed increased in reactive macrophage in the high fat diet
adipose tissue. IFNc has an increasingly apparent role in
regulating not only adipocyte cytokine secretion including TNFa
but also insulin resistance and infiltration of T cells into obese
adipose tissue [92,93,94]. Elevated IL-13 expression is a hallmark
of recently defined alternative M2 phenotype macrophage in
obese adipose tissue [95]. Although APP stimulation did not alter
adipocyte phenotype in our hands a more extensive assessment
would likely identify APP-dependent changes in adipocytes
relevant to obesity. One interesting possibility is that an APP-
APP dependent interaction between adipocytes and macrophage is
involved in activating both cell types. That is, APP on macrophage
may interact with APP on adipocytes in a complex trans APP-APP
interaction as APP can act as a receptor for monocytic lineage cells
[43]. It is known that although adipocytes are quite capable of
secreting a range of inflammatory molecules [96] that macro-
phage-adipocyte interaction can potentiate inflammatory changes
that can occur during obesity and metabolic disorder [97].
Determination of specific roles for APP in macrophage and
adipocyte changes during high fat diet feeding might be addressed
in future work through the use of APP knockout mice or cell
specific APP deletion or even expression of mutant forms of APP
such as those associated with AD.
A final interesting speculation is that if APP and/or Ab levels
increase in adipose tissue during obesity and AD and coordinated
expression is tightly regulated between brain and fat then it is not
unreasonable to predict that monitoring APP expression and
metabolism in adipose tissue could serve as a surrogate for brain
with regard to assessing efficacy of particular drug interventions or
monitoring disease pathophysiology of obesity or AD. For instance,
it is possible that a portion of any generated Ab in adipose tissue
could accumulate as amyloid deposits in either obese or AD
individuals. It is well established that adipose tissue can accumulate
amyloid proteins, for example, in individuals with rheumatoid
arthritis which is often assessed via needle biopsy [98,99].
Materials and Methods
Ethics Statement
The investigation conforms to the National Research Council of
the National Academies Guide for the Care and Use of Laboratory
Animals (8
th edition). Animal use was approved by the University of
North Dakota IACUC, protocol #1003-1.
Materials
Anti-b-Amyloid Precursor Protein (APP) antibody was pur-
chased from Invitrogen (Carlsbad, CA, USA). Anti-mouse IgM
(goat), anti-rabbit (goat), anti-goat (bovine), anti-rat (goat), and
anti-mouse (bovine) horseradish peroxidase-conjugated secondary
antibodies, Cox-2, GAPDH, a-tubulin, and b actin antibodies
were purchased from Santa Cruz Biotechnology (Santa Cruz, CA,
USA). Elite Vectastain ABC Avidin and Biotin, Vector VIP,
Vector DAB, biotinylated anti-rabbit, anti-mouse, and anti-rat
antibodies were purchased from Vector Laboratories Inc (Burlin-
game, CA, USA). Synaptophysin and bIII tubulin antibodies were
purchased from Chemicon international, Inc (Temecula, CA,
USA). CD45 antibody was purchased from BD Biosciences
Pharmingen (San Jose, CA, USA). TNF-a antibody was purchased
from Abcam Inc (Cambridge, MA, USA). CD68 antibody was
purchased from AbD Serotec (Oxford, UK). iNOS antibody was
purchased from Alexis Biochemicals (San Diego, CA, USA).
GFAP and PSD95 antibody was purchased from Cell Signaling
Technology Inc (Danvers, MA, USA). PHF-1 antibody was a gift
from Dr. Peter Davies (Albert Einstein College of Medicine, NY).
Cox-2 and Prostaglandin (PG) E2d4 were purchased from
Cayman Chemical (Ann Arbor, MI, USA). b-Amyloid (Ab),
rodent specific polyclonal antibody (SIG-39151) was purchased
from Covance (Emeryville, CA, USA).
Figure 10. APP and CD68 immunoreactivity co-localized in
subcutaneous (abdominal) and visceral (heart) fat from high
fat diet fed mice. C57BL6/J mice at 6 weeks of age and weight
matched were fed, ad libitum, a control (5.5% fat/weight) or high fat
(21.2% fat/weight) diet for 22 weeks. Subcutaneous abdominal and
visceral pericardial adipose tissue samples were collected, immersion
fixed, serially sectioned and immunostained using anti-CD68 antibody
and binding visualized using DAB as the chromogen. For double-
labeling, tissue sections were stripped using 0.2N HCl and subsequently
immunostained using anti-APP antibody and binding visualized using
Vector VIP as the chromogen. A representative image from 12 animals
per condition is shown. The brown arrow indicates CD68 immunore-
activity, the red arrow indicates APP immunoreactivity and the black
arrow indicates double-label of CD68 and APP antibody binding.
doi:10.1371/journal.pone.0030378.g010
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APP
tm1Dbo/J homozygous (APP
-/-) miceand wild type (C57BL6/
J) mice were purchased from Jackson Laboratory. Mice were
provided food and water ad libitum and housed in a 12 hour light/
dark cycle.
High Fat vs. Control Diet Feeding
At six weeks of age, 34 male weight matched C57BL6/J wild
type mice were placed on either a 21.2% by weight high fat diet
(Harlan Teklad TD.88137) or a 5.5% by weight regular fat diet
(Harland Teklad 8640), ad libitum. 12 animals in each group were
weighed each week for 22 weeks.
Western Blotting
After 22 weeks the animals were perfused with PBS containing
CaCl2 and brain, hippocampus, visceral (pericardial or heart) fat
and subcutaneous (abdominal or stomach) fat were collected and
lysed using ice cold RIPA buffer (20 mM Tris, pH 7.4, 150 mM
NaCl, 1 mM Na3VO4, 10 mM NaF, 1 mM EDTA, 1 mM
EGTA, 0.2 mM phenylmethylsulfonyl fluoride, 1% Triton, 0.1%
SDS, and 0.5% deoxycholate) with protease inhibitors (AEBSF
1 mM, Aprotinin 0.8 mM, Leupeptin 21 mM, Bestatin 36 mM,
Pepstatin A 15 mM, E-64 14 mM). To remove insoluble material
cell lysates were sonicated and centrifuged (14,000 rpm, 4uC,
10 min). The Bradford method [100] was used to quantify protein
concentrations. Proteins were resolved by 10% SDS-PAGE and
transferred to polyvinylidene difluoride membranes for Western
blotting using anti-APP, iNOS, Cox-2, synaptophysin, PSD95,
phospho-tau (PHF-1), TNF-a, GFAP, CD68, bIII tubulin (loading
control), a-tubulin (loading control), GAPDH (loading control).
Antibody binding was detected with enhanced chemiluminescence
(GE Healthcare, Piscataway, NJ, USA). In some instances,
antibodies were stripped from blots with 0.2 NaOH, 10 min,
25uC, for antibody reprobing. Western blots were quantified using
Adobe Photoshop software. In order to be able to compare all the
samples per dietary condition for each antibody it was necessary to
run two gels per antibody probe. To minimize any variability
across gels, control and high fat diet samples were resolved and
transferred for individual antibody comparisons at the same time
in the same gel running/transfer apparatus. The blots were
incubated in the same antibody solution and visualized and
quantified at the same time. This minimized the variability of
across-gel comparisons. Optical density of bands were normalized
against their respective loading controls and averaged (+/2SD).
Immunohistochemistry
After 22 weeks the animals were perfused with PBS containing
CaCl2 and brain, hippocampus, visceral (pericardial/heart) fat and
subcutaneous (abdominal/ stomach) fat was collected and
immersion fixed for 24 hrs in 4% paraformaldehyde, cryopro-
tected through two successive 30% sucrose changes. Brains were
embedded in gelatin and serially sectioned (40 mm) via freezing
microtome and immunostained using anti-APP, b-amyloid, CD68,
iNOS, Cox-2, or GFAP antibodies or respective secondary only
antibodies. Subcutaneous and visceral fat tissue samples were
serially cryosectioned (10 mm) or paraffin embedded and sectioned
(7 mm) for immunostaining with anti-APP, b-amyloid, CD45 or
CD68 antibodies or respective secondary only antibodies.
Antibody binding in brain or fat was visualized using Vector
Figure 11. Secreted levels of GM-CSF, IFNc, and IL-13 increased
in media from peritoneal macrophage stimulated with APP
agonist antibody, 22C11, compared to IgG1 isotype control.
Non-elicited peritoneal macrophage were stimulated with 1 mg/mL
IgG1 or 1 mg/mL 22C11 APP agonist antibody overnight and the media
was removed and used according in a commercial antibody-based 40
cytokine antibody array. A representative dot blot per each condition is
shown. The optical densities of individual cytokine detection spots were
normalized against their respective positive controls per blot and
averaged (+/2SD) and graphed from 5 animals in each group. Data
were analyzed via unpaired two-tailed t-test. *p,0.05, **p,0.01.
doi:10.1371/journal.pone.0030378.g011
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CA, USA). For double labeling, immunostained tissue was
stripped of antibodies with 0.2N HCl for 10 min prior to
processing with the second primary antibody incubation and
visualization steps. Images were taken using an upright Leica
DM1000 microscope and Leica DF320 digital camera system.
Figures were made using Adobe Photoshop 7.0 software.
Macrophage Isolation and Stimulation
At 22 weeks non-elicited peritoneal macrophage were rinsed
from the peritoneal cavity with sterile PBS and allowed to adhere
to tissue culture wells for 2–3 hours in DMEM/F12 with 10% FBS
and 5% horse serum. Nonadherent and non-macrophage cells
were rinsed from the wells using ice cold DMEM/F12. The
remaining macrophage were scraped from the wells and replated
for stimulations.
Microglia Isolation and Stimulation
Acutely isolated microglia were collected at 22 weeks as previously
described [35]. Briefly, cortices were isolated, finely minced and
filtered through 140 and 70 um filters then gently digested with
DNAseIandcollagenasebeforebeingseparatedonaPercollgradient.
The microglial layer was collected, counted and used for stimulations.
Enzyme-linked Immunosorbent Assay
Isolated microglia and macrophage were plated (40,000 cell/
150 mL) in DMEM/F12 overnight then media was collected for
quantifying secreted TNF-a according to the manufacturer’s
protocol (R&D Systems, Minneapolis, MN, USA).
Prostaglandin Analysis
PG were analyzed as previously described [101]. Brain samples
(were homogenized in 1 mL of saline and extracted with 2 mL of
Figure 12. APP activation with agonist antibody did not alter cytokine secretion, viability, or Oil Red O staining of primary murine
abdominal subcutaneous adipocytes. Adipocytes were harvested from subcutaneous abdominal fat from C57BL6/J mice and cultured in DMEM/
F12 with serum and antibiotics for one week. Cells were then placed into serum free DMEM/F12 and unstimulated (control) or stimulated for 24 hr
with 1 mg/mL IgG1 (isotype control) or 1mg/mL 22C11 (APP agonist antibody). After 24 hours (A) Secreted LDH released into the media normalized
against cellular LDH was quantified to assess changes in cell viability upon APP stimulation. (B) Changes in secreted TNFa levels were also quantified
from the media as a result of APP stimulation. (C) Cells were also fixed, stained with Oil Red O and DAPI counterstain and changes in Oil Red O
absorbance (510 nm) normalized to DAPI absorbance (358/461 nm) were quantified via plate reader. (D) Representative images of Oil Red O and
cresyl violet counterstained adipocytes are shown following 24 hr IgG1 and 22C11 stimulation. Data are shown as mean (+/2SD) and are
representative of three independent experiments. Data were analyzed via a one-way ANOVA.
doi:10.1371/journal.pone.0030378.g012
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following with 2 mL of chloroform with 0.005% BHT. PGE2d4
was used as internal standard. After extraction, the samples were
dried under a stream of nitrogen and then redissolved in 30 mLo f
acetonitrile:water (1:2 by volume). Reverse-phase LC electrospray
ionization mass spectrometry was used for PG analysis. The PG
were separated on a Luna C-18(2) (3 mm column, 100 A pore
diameter, 150 x 2.0 mm) (Phenomenex, Torrance, CA, USA) with
security guard cartridge system (Phenomenex, Torrance, CA,
USA). The LC system consisted of an Agilent 1100 series LC
pump with a wellplate autosampler (Agilent Technologies, Santa
Clara, CA). The solvent system was composed of 0.1% formic acid
in water (solvent A) and 0.1% formic acid in acetonitrile (solvent
B). The flow rate was 0.2 mL/min. The separation program
started with 10% of solvent B. At 2 min, the percentage of B was
increased to 65% over 8 min, at 15 min the percentage of B was
increased to 90% over 5 min, and at 35 min it was reduced to
10% over 2 min. Equilibration time between runs was 13 min.
Mass spectrometry analysis was performed using a quadrapole
mass spectrometer (API3000, Applied Biosystem, Foster City, CA,
USA) equipped with a TurboIonSpray ionization source. Analyst
software version 1.5.1 (Applied Biosystem, Foster City, CA, USA)
was used for instrument control, data acquisition, and data
analysis. The mass spectrometer was optimized in the multiple
reaction-monitoring mode. The source was operated in negative
ion electrospray mode at 450uC, electrospray voltage was
24250 V, nebulizer gas was 8 L/min and curtain gas was
11 L/min. Declustering potential, focusing potential, and entrance
potential were optimized individually for each analyte. The
quadrupole mass spectrometer was operated at unit resolution.
Antibody-based Cytokine Array
At 7 months of age non-elicited peritoneal macrophage were
rinsed from the peritoneal cavity with sterile PBS, counted, plated
at 1.5610
6cells/well/6well dish and allowed to adhere to the tissue
culture wells for 2–3 hours in DMEM/F12. Nonadherent and
non-macrophage cells were rinsed from the wells using ice-cold
DMEM/F12. Media containing isotype negative control 1 mg/mL
IgG1 (Millipore, Billerica, Massachusetts USA) or APP agonist
antibody 1 mg/mL 22C11 (Millipore, Billerica, Massachusetts
USA) was added to the wells overnight for stimulation. The media
was removed and used according to the manufacturer’s protocol
(Ray Biotech, Norcross, GA, USA) for the cytokine arrays. 5
animals per stimulation were analyzed. Optical density of dots
were normalized against their respective positive controls and
averaged (+/-SD).
Adipocyte Isolation and Stimulation
Adipocyte cultures were generated via a modification of a prior
method [102]. Subcutaneous abdominal adipose tissue was
removed from the mice, rinsed with sterile Hanks Balanced Salt
Solution (HBSS), minced with scissors, placed in 35 mm plates and
incubated for 1 hr @ 37C on a rocker in a sterile enzyme solution
(5mM glucose, 1.5% BSA, 5 mg collagenase in HBSS). Following
incubation, adipocytes were spun at 186xg for 2 min and the lower
layer was removed and discarded. The upper layer was resuspened
insterile HBSStorepeatthespin,rinsewasrepeatedtwotimes.The
finalupperlayerwasresuspended inDMEM/F12+ 10%FBS+5%
horse serum + antibiotics (0.05 mg penicillin/0.05 mg streptomy-
cin/0.01mg neomycin/mL). The cells were added to 96 well plates,
with DMEM/F12 + 10% FBS + 5% horse serum + antibiotics. The
plates were then completely filled to the brim with media, covered
with sterile parafilm, and inverted for 1 week to allow floating
adipocytes to adhere to the tissue culture treated component of the
plastic wells. After 1 week, the media was removed and the plates
place right-side up so that adipocytes were now available for
stimulation. The cells were treated with serum free DMEM/F12
and unstimulated (control) or stimulated for 24 hr with 1 mg/mL
IgG1 (isotype negative control) or 1 mg/mL 22C11 (APP agonist
antibody). After 24 hours, secreted LDH was measured according
to the manufacture protocol for both the media and the cell lysates
using commercial reagents (Promega, Madison, WI). Secreted
media LDH values were normalized against cellular LDH values.
Media was also collected for ELISA analysis quantifying secreted
TNF-a according to the manufacturer’s protocol (R&D Systems,
Minneapolis, MN). Cells were also fixed, stained with Oil Red O
(Alfa Aesar, Ward Hill, MN, USA) and DAPI (49,6-diamidino-2-
phenylindole) (Sigma Aldrich, St. Louis, MO, USA) counterstained
and changes in Oil Red O absorbance (510 nm) normalized to
DAPI absorbance (358/461 nm) were quantified via plate reader.
Experiments were repeated three independent times.
Statistical Analysis
The data were analyzed by unpaired two-tailed t-test with or
without Welch correction for unequal variance as required. When
three groups were analyzed one-way ANOVA with Holm-Sidak
post hoc test or a Kruskal-Wallis nonparametric ANOVA with a
Dunn’s post hoc test were utilized for analysis.
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